Updated daily — Research, trials & safety

The definitive guide to ibogaine treatment & research

Clinical evidence, safety protocols, legal status in 8+ countries, 40+ active trials, and a vetted clinic directory — all in one place. No affiliate bias. No hype.

Explore the research Understand the risks
40+
Clinical trials tracked
8
Countries covered
3
Alkaloids profiled
Daily
Trial & news updates

Explore

Everything you need to know about ibogaine

From pharmacology to legal access — research-backed, cited, and updated regularly.

Learn

Research articles covering treatment, neurochemistry, safety protocols, and the latest FDA and clinical developments.

Browse articles →

Drug Reference

Detailed pharmacology profiles for ibogaine, noribogaine, and ibogamine — mechanisms, interactions, legal status.

View profiles →

Conditions

Evidence pages for opioid addiction, depression, PTSD, and Parkinson’s — what the trials show and what remains unknown.

See conditions →

Safety & Screening

Cardiac risks, QTc prolongation, drug interactions, contraindications, and what pre-treatment screening is required.

Safety protocols →

Legality

Current legal status in the US, Mexico, Portugal, Netherlands, Costa Rica, Canada, New Zealand, and South Africa.

Check your country →

Clinic Directory

Vetted treatment centers with pricing, accreditation details, cardiac screening standards, and conditions treated.

Find a clinic →

Clinical Trials

Live tracker of 40+ ibogaine studies on ClinicalTrials.gov. Status, phase, sponsor, and key findings — updated daily.

View active trials →

Compare Treatments

Objective comparisons of ibogaine vs methadone, suboxone, ketamine, and psilocybin — mechanism, evidence, access, cost.

Compare options →

Latest

Recently published

New research, condition pages, and country updates added regularly.

Loading recent content…
View all articles →

Stay ahead of ibogaine developments

FDA news, trial results, and safety alerts — delivered when it matters. No spam. Unsubscribe any time.

Quick answers

Frequently asked questions

Ibogaine is a naturally occurring psychoactive alkaloid extracted from the root bark of Tabernanthe iboga, a plant used for centuries in Bwiti spiritual ceremonies in Gabon and Cameroon. In modern medicine it is studied primarily as a treatment for opioid use disorder, with 40+ active clinical trials as of 2026. It is distinct from other psychedelics in its duration (24–36 hours), its direct action on opioid receptors, and its potential to interrupt physical dependence in a single session.
Ibogaine is a Schedule I controlled substance in the United States, making it illegal to manufacture, distribute, or possess outside of FDA-approved research. However, the regulatory landscape is shifting rapidly — ibogaine received attention from the VA and Department of Defense following promising results in veteran PTSD and TBI studies, and the FDA has designated multiple ibogaine trials as breakthrough therapies. Access for treatment currently requires travel to countries where ibogaine is legal. See our US legality page for current details.
Ibogaine prolongs the QTc interval on an ECG, which can lead to fatal ventricular arrhythmias (torsades de pointes) in susceptible individuals. Most documented fatalities involved pre-existing cardiac conditions, concurrent substance use (especially opioids, stimulants, or serotonergic drugs), or inadequate screening. Reputable treatment centers require a full cardiac evaluation including 12-lead ECG, potassium and magnesium levels, and medical history review before any ibogaine administration. See our safety section for screening checklists.
The most popular destinations for ibogaine treatment are Mexico (unscheduled, largest concentration of clinics), Portugal (decriminalized for personal use), the Netherlands (legal for religious and therapeutic use under certain conditions), Costa Rica (unscheduled), and New Zealand (unscheduled). Canada permits ibogaine under specific exemptions. South Africa has no federal scheduling. Legal status can change — always verify with current local counsel before traveling. Our legality section covers each country in detail.
Ibogaine treatment typically costs between $3,000 and $15,000 USD, depending on location, duration of stay, level of medical supervision, and integration support offered. Mexican clinics generally range from $3,000–$8,000 for a week-long residential program. European and North American facilities with higher medical accreditation often cost more. Cardiac screening fees, travel, and post-treatment integration therapy are usually additional costs to budget for. See our clinic directory for specific pricing from vetted providers.